Problems Persist Despite Gains In Oral Anticoagulant Use

Although significant progress has been made in recent years, a new survey from the European Society of Cardiology finds that there are still too many atrial fibrillation patients who are not taking the best medications to reduce their elevated risk of stroke. Many elderly patients are not receiving oral anticoagulants-- either traditional warfarin or one of the newer anticoagulants (Pradaxa, Boehringer Ingelheim, Xarelto, Johnson & Johnson; and Eliquis (Pfizer and BristolMyers Squibb)-- and overall too many patients are still taking aspirin, despite the fact that it is not recommended for this group of patients.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news